Indian stocks: Visit www.stage2stocks.com →

bioAffinity Technologies, Inc.

Stage 4 · Declining · week 20

As of Oct 22, 2026, bioAffinity Technologies is in Stage 4, the downtrend phase, now in week 20 (since Jun 4, 2026). It closed at $3.17, 95.5% below its 52-week high and below its 200-day average, which is falling.

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analys… More about the company

$3.17
-12.67% today
$4.1M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is BIAF early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 17w
S2 16w
S4 45w
S4 29w
S4 20w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 17w → S1 11w → S2 16w → S3 4w → S2 3w → S3 5w → S4 45w → S1 3w → S4 29w → S1 11w → S4 20w current
Total tracked: 165 weeks across 11 stage runs.

BIAF among Diagnostics & Research41st of 44 by relative strength

All 44 →
Stocks in Diagnostics & Research ranked by relative strength, with stage and one-month change
#StockStageRS1M
1CDNAStage 2 · wk 2499+27.3%
2BDSXStage 2 · wk 1898−18.3%
3ILMNStage 2 · wk 2497+5.5%
4GHStage 2 · wk 2197−7.6%
5NTRAStage 2 · wk 2096+2.7%
6CRLStage 2 · wk 1692+22.5%
7RVTYStage 2 · wk 1890+10.7%
8PSNLStage 2 · wk 1790−3.2%
…41BIAFStage 4 · wk 206−60.1%
vs 52W High
-95.5%
$3.17 lo$71.10 hi
95.5% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 20
1w13w26w
Week 20, established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-83.9%
200 DMA: $19.74 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.02x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-60.1%
3M
-68.0%
6M
-90.8%
YTD
-82.7%
1Y
-92.5%
Scan Membership
Breakout Watch
Latest: 2024-07-26
2 appearances in last 60 days. First seen: 2024-03-04.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 20 · Vol 0.02x
2026-10-21S4
Wk 20 · Vol 0.01x
2026-10-20S4
Wk 20 · Vol 0.02x
2026-10-19S4
Wk 19 · Vol 0.01x
2026-10-16S4
Wk 19 · Vol 0.02x
2026-10-15S4
Wk 19 · Vol 0.06x
2026-10-14S4
Wk 19 · Vol 0.02x
2026-10-13S4
Wk 19 · Vol 0.19x
2026-10-12S4
Wk 18 · Vol 0.06x
2026-10-09S4
Wk 18 · Vol 0.14x
2026-10-08S4
Wk 18 · Vol 8.84x
2026-10-07S4
Wk 18 · Vol 0.02x
Moving averages & range
50 DMA
$6.54
200 DMA
$19.74
52W High
$71.10
52W Low
$3.17
5D Low
$3.17
Resistance levels (recent highs)
20d High
$7.93
60d High
$15.27
120d High
$32.70
250d High
$71.10
Next resistance
+150.2%
to 20d High
ROE
-1860.2%
Profit margin -257.3%
Dividend Yield
0.00%
P/B 0.4

bioAffinity Technologies: quick answers

What stage is bioAffinity Technologies in?

As of Oct 22, 2026, bioAffinity Technologies (BIAF) is in Stage 4, the downtrend phase. It entered Stage 4 on Jun 4, 2026 and is in week 20. What the four stages mean

Is bioAffinity Technologies in an uptrend?

No. bioAffinity Technologies is in a Stage 4 downtrend. It trades 83.9% below its 200-day average, which is falling.

How far is bioAffinity Technologies from its 52-week high?

bioAffinity Technologies closed at $3.17 on Oct 22, 2026, 95.5% below its 52-week high of $71.10. Its 52-week low is $3.17.

How has bioAffinity Technologies performed over the past year?

As of Oct 22, 2026, bioAffinity Technologies is down 92.5% over the past year and down 82.7% so far in 2026.

Which sector and industry is bioAffinity Technologies in?

bioAffinity Technologies is in the Diagnostics & Research industry, part of the Health Care sector.

About this companyHealth Care· Diagnostics & Research

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.